These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 33236048)

  • 21. Why restrict medical effective altruism?
    Quigley T
    Bioethics; 2024 Jun; 38(5):452-459. PubMed ID: 38463001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethics and Professionalism on the Frontline: Controlled Human Infection Trials in COVID-19 Vaccine Development: Ethical Considerations.
    Lucido C
    S D Med; 2020 Oct; 73(10):490-492. PubMed ID: 33264530
    [No Abstract]   [Full Text] [Related]  

  • 23. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Broockman D; Kalla J; Guerrero A; Budolfson M; Eyal N; Jewell NP; Magalhaes M; Sekhon JS
    Vaccine; 2021 Jan; 39(2):309-316. PubMed ID: 33334616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparatory phase for clinical trials of COVID-19 vaccine in Nepal.
    Gupta GP; Shah Y; Pant DK; Lekhak S; Shahi R; Mandal A; Poudel P; Dumre SP; Pandey K; Pandey BD
    Hum Vaccin Immunother; 2021 Feb; 17(2):418-419. PubMed ID: 32966155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
    Forman R; Shah S; Jeurissen P; Jit M; Mossialos E
    Health Policy; 2021 May; 125(5):553-567. PubMed ID: 33820678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant protein vaccines, a proven approach against coronavirus pandemics.
    Pollet J; Chen WH; Strych U
    Adv Drug Deliv Rev; 2021 Mar; 170():71-82. PubMed ID: 33421475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Payment in challenge studies: ethics, attitudes and a new payment for risk model.
    Grimwade O; Savulescu J; Giubilini A; Oakley J; Osowicki J; Pollard AJ; Nussberger AM
    J Med Ethics; 2020 Dec; 46(12):815-826. PubMed ID: 32978306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peruvian COVID-19 vaccine scandal spreads.
    Chauvin L
    Lancet; 2021 Feb; 397(10276):783. PubMed ID: 33640052
    [No Abstract]   [Full Text] [Related]  

  • 30. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.
    Iserson KV
    Camb Q Healthc Ethics; 2021 Jan; 30(1):59-68. PubMed ID: 32498742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
    Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
    Singh JA; Upshur REG
    Lancet Infect Dis; 2021 Apr; 21(4):e103-e109. PubMed ID: 33306980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "No" to placebo-controlled trials of Covid-19 vaccines.
    Ahmad A; Dhrolia MF
    Indian J Med Ethics; 2021; VI(2):1-7. PubMed ID: 33908356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
    Gallagher ME; Sieben AJ; Nelson KN; Kraay ANM; Orenstein WA; Lopman B; Handel A; Koelle K
    Nat Med; 2021 Jan; 27(1):4-5. PubMed ID: 33230343
    [No Abstract]   [Full Text] [Related]  

  • 35. Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics.
    Evans NG
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethical considerations for epidemic vaccine trials.
    Monrad JT
    J Med Ethics; 2020 Jul; 46(7):465-469. PubMed ID: 32414757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials.
    Gong W; Aspatwar A; Wang S; Parkkila S; Wu X
    Expert Rev Vaccines; 2021 Jul; 20(7):857-880. PubMed ID: 34078215
    [No Abstract]   [Full Text] [Related]  

  • 38. Ethical guidelines for deliberately infecting volunteers with COVID-19.
    Richards AD
    J Med Ethics; 2020 Aug; 46(8):502-504. PubMed ID: 32461245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 vaccine trials must include helminth-infected cohorts.
    Egwang TG; Owalla TJ; Kemigisha M
    Nat Immunol; 2022 Feb; 23(2):148. PubMed ID: 35075281
    [No Abstract]   [Full Text] [Related]  

  • 40. A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates.
    Berry DA; Berry S; Hale P; Isakov L; Lo AW; Siah KW; Wong CH
    PLoS One; 2020; 15(12):e0244418. PubMed ID: 33362278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.